Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.

Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451) / E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, R. Paoletti. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 23:6(1981 Sep 15), pp. 549-553.

Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)

E. Tremoli
Primo
;
S. Colli
Penultimo
;
R. Paoletti
Ultimo
1981-09-15

Abstract

Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.
Experimental venous thrombosis; Thrombin inhibitors
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/193697
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact